Table 4. Clinical and pathological characteristics of patients with the World Health Organization (WHO)-defined ‘myelodysplastic syndrome with isolated del(5q)' and associated MPL mutations.
| Variable | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
| Age/sex | 76/F | 72/F | 75/F |
| Molecular analysis | MPLW515L | MPLW515L | MPLW515L |
| JAK2V617F | |||
| Transfusion need at presentation | No | No | Yes |
| Hemoglobin (g per 100 ml) | 11.0 | 11.3 | 7.6 |
| MCV (fl) | 104 | 110 | 102 |
| Leukocyte count ( × 109 cells per l) | 5.5 | 3.2 | 3.8 |
| Absolute lymphocyte count ( × 109 cells per l) | 2.6 | 0.9 | 1.2 |
| Absolute monocyte count ( × 109 cells per l) | 0.6 | 0.8 | 1.0 |
| Platelet count ( × 109 cells per l) | 340 | 326 | 417 |
| Serum ferritin (μg l−1) | 340 | 230 | 3500 |
| 5q break point | 5q33 | 5q33 | 5q33 |
| BM dyserythropoiesis | Yes | No | No |
| BM dysgranulopoiesis | Yes | No | No |
| BM dysmegakaryopoiesis | No | Yes | Yes |
| Disease transformation | No | No | No |
| Survival (months) | 171 | 25 | 61 |
| Status at last follow-up | Alive | Alive | Alive |
Abbreviations: BM, bone marrow; JAK2, janus kinase 2; MCV, mean corpuscular volume; MPL, myeloproliferative leukemia virus oncogene (thrombopoietin receptor).